Overview

Location [1]
22q11.22
Protein [2]
Melanoma antigen preferentially expressed in tumors
Synonyms [1]
MAPE, OIP-4, OIP4, CT130

PRAME is altered in 0.29% of all cancers.

The most common alterations in PRAME are PRAME Loss (0.05%) and PRAME Amplification (0.03%) [3].

PRAME GENIE Cases - Top Alterations

Significance of PRAME in Diseases

Malignant Solid Tumor +

Acute Myeloid Leukemia +

Ovarian Carcinoma +

Refractory Anemia With Excess Blasts-1 +

Refractory Anemia With Excess Blasts-2 +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.